JP2016522196A - 左室リモデリングの予防または治療のための方法 - Google Patents

左室リモデリングの予防または治療のための方法 Download PDF

Info

Publication number
JP2016522196A
JP2016522196A JP2016513938A JP2016513938A JP2016522196A JP 2016522196 A JP2016522196 A JP 2016522196A JP 2016513938 A JP2016513938 A JP 2016513938A JP 2016513938 A JP2016513938 A JP 2016513938A JP 2016522196 A JP2016522196 A JP 2016522196A
Authority
JP
Japan
Prior art keywords
arg
lys
phe
dmt
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016513938A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016522196A5 (enExample
Inventor
ディー トラヴィス ウィルソン
ディー トラヴィス ウィルソン
ロバート エイ クロナー
ロバート エイ クロナー
Original Assignee
ステルス バイオセラピューティックス コープ
ステルス バイオセラピューティックス コープ
ハート インスティテュート グッド サマリタン ホスピタル
ハート インスティテュート グッド サマリタン ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ステルス バイオセラピューティックス コープ, ステルス バイオセラピューティックス コープ, ハート インスティテュート グッド サマリタン ホスピタル, ハート インスティテュート グッド サマリタン ホスピタル filed Critical ステルス バイオセラピューティックス コープ
Publication of JP2016522196A publication Critical patent/JP2016522196A/ja
Publication of JP2016522196A5 publication Critical patent/JP2016522196A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2016513938A 2013-05-14 2013-10-22 左室リモデリングの予防または治療のための方法 Pending JP2016522196A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361823305P 2013-05-14 2013-05-14
US61/823,305 2013-05-14
PCT/US2013/066212 WO2014185952A1 (en) 2013-05-14 2013-10-22 Methods for the prevention or treatment of left ventricle remodeling

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018210291A Division JP2019052157A (ja) 2013-05-14 2018-11-08 左室リモデリングの予防または治療のための方法

Publications (2)

Publication Number Publication Date
JP2016522196A true JP2016522196A (ja) 2016-07-28
JP2016522196A5 JP2016522196A5 (enExample) 2017-02-23

Family

ID=51898747

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016513938A Pending JP2016522196A (ja) 2013-05-14 2013-10-22 左室リモデリングの予防または治療のための方法
JP2018210291A Pending JP2019052157A (ja) 2013-05-14 2018-11-08 左室リモデリングの予防または治療のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018210291A Pending JP2019052157A (ja) 2013-05-14 2018-11-08 左室リモデリングの予防または治療のための方法

Country Status (6)

Country Link
US (4) US20160256514A1 (enExample)
EP (2) EP3586864A1 (enExample)
JP (2) JP2016522196A (enExample)
CN (2) CN105579054A (enExample)
CA (1) CA2912386A1 (enExample)
WO (1) WO2014185952A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019052157A (ja) * 2013-05-14 2019-04-04 ステルス バイオセラピューティックス コープ 左室リモデリングの予防または治療のための方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180318381A1 (en) * 2015-10-23 2018-11-08 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Methods of Treatment of Rhabdomyolysis
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
CN108042525B (zh) * 2017-12-20 2020-09-01 岳红 一种治疗心肌梗死后心室重塑的药物组合物
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
GB202000945D0 (en) * 2020-01-22 2020-03-04 Univ Oslo Treatment of cardiac remodelling
EP4168425A4 (en) * 2020-06-17 2024-06-19 Stealth BioTherapeutics Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DYSTROPHY

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006569A1 (en) * 2010-07-09 2012-01-12 Stealth Peptides International, Inc. Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
WO2013049697A1 (en) * 2011-09-29 2013-04-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
EP3260127B1 (en) * 2005-09-16 2019-05-01 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method of treating cerebral ischemia
CN102711785A (zh) * 2009-10-05 2012-10-03 康奈尔大学 预防或治疗心力衰竭的方法
EP3100739A1 (en) * 2009-12-31 2016-12-07 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
CN103751763A (zh) * 2009-12-31 2014-04-30 康肽德生物医药技术有限公司 用于预防或治疗血管阻塞损伤的方法
EP3560508A1 (en) * 2010-03-15 2019-10-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US20140045758A1 (en) * 2011-02-21 2014-02-13 The Trustees Of Columbia University In The City Of New York Methods for Treating and Preventing Cardiac Dysfunction in Septic Shock
CN105579054A (zh) * 2013-05-14 2016-05-11 康德生物医疗技术公司 预防或治疗左心室重塑的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006569A1 (en) * 2010-07-09 2012-01-12 Stealth Peptides International, Inc. Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
WO2013049697A1 (en) * 2011-09-29 2013-04-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ＪＯＵＲＮＡＬ ＯＦ ＴＨＥ ＡＭＥＲＩＣＡＮ ＣＯＬＬＥＧＥ ＯＦ ＣＡＲＤＩＯＬＯＧＹ（ＪＡＣＣ, vol. Ｖｏｌ．６１，Ｎｏ．１０，Ｓｕｐｐｌ．, JPN6017028985, 12 March 2013 (2013-03-12), pages 709, ISSN: 0003977916 *
日本冠疾患学会雑誌, vol. 18, no. 3, JPN6017028984, 2012, pages 239 - 244, ISSN: 0003977917 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019052157A (ja) * 2013-05-14 2019-04-04 ステルス バイオセラピューティックス コープ 左室リモデリングの予防または治療のための方法

Also Published As

Publication number Publication date
HK1222794A1 (en) 2017-07-14
JP2019052157A (ja) 2019-04-04
US20220296671A1 (en) 2022-09-22
CA2912386A1 (en) 2014-11-20
EP2996707B1 (en) 2019-09-11
US20160256514A1 (en) 2016-09-08
US20250319152A1 (en) 2025-10-16
CN110051843A (zh) 2019-07-26
EP3586864A1 (en) 2020-01-01
WO2014185952A1 (en) 2014-11-20
EP2996707A1 (en) 2016-03-23
US20190358286A1 (en) 2019-11-28
EP2996707A4 (en) 2016-12-07
CN105579054A (zh) 2016-05-11

Similar Documents

Publication Publication Date Title
US12102659B2 (en) Methods for the prevention or treatment of heart failure
JP7381652B2 (ja) バース症候群の予防または治療のための方法及び組成物
US20250319152A1 (en) Methods for the prevention or treatment of left ventricle remodeling
US11266709B2 (en) Methods for the regulation of matrix metalloproteinase expression
US20200113966A1 (en) Methods and compositions for regulating srca2a expression levels in myocardial infarction
HK1222794B (en) Methods for the prevention or treatment of left ventricle remodeling

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181108

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190128

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190215